IFNA1 and systemic lupus erythematosus: Phase II randomized controlled trials in adult SLE patients showed that anti-IFN therapy (sifalimumab and anifrolumab) (27) and some JAK inhibitors (8, 9, 17, 18) provided beneficial effects.